AlkaBurst2.0 – A game changing bioreactor for sustainable production of active p...
AlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approach
Alkion, a revolutionary biotech company, is developing a breakthrough biorefinery to produce top quality active pharmaceutical ingredients (API) and extracts in plants in a sustainable and cost-effective way. Our core technology c...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SEB
Scalable and Eco-friendly Bioproduction
2M€
Cerrado
FUTURE-PHARMA
Exploiting plants for the production of future generation re...
3M€
Cerrado
RTC-2017-6173-1
Producción de Cannabinoides con aplicación farmacológica med...
342K€
Cerrado
BIO2017-82374-R
NUEVOS BIOPROCESOS SOSTENIBLES Y ECOLOGICOS BASADOS EN LAS B...
109K€
Cerrado
Rhizomia
A novel cost efficient bioreactor to accelerate growth of va...
71K€
Cerrado
greenerRPP
Greener, more sustainable platforms for high-value recombina...
Cerrado
Información proyecto AlkaBurst2.0
Duración del proyecto: 24 meses
Fecha Inicio: 2022-10-26
Fecha Fin: 2024-10-31
Líder del proyecto
ALKION BIOINNOVATIONS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Alkion, a revolutionary biotech company, is developing a breakthrough biorefinery to produce top quality active pharmaceutical ingredients (API) and extracts in plants in a sustainable and cost-effective way. Our core technology combines our disruptive patented automated bioreactor-AlkaBurst2.0 with unique knowhow on gene expression methods, culture media and extraction. Our process offers high productivity and a low carbon footprint.
The pharma industry is carbon intensive with recurring problems of quality & safety. Moreover, many critical APIs are outsourced to Asia to cut costs. AlkaBurst2.0 allows a local standardised production of safe & clean APIs in its automated process saving 75% time, 80% space, 95% electricity, 98% water.
We first validated the production for Covid-19 natural vaccine adjuvants QS21/7, cannabinoids & certain recombinant proteins for the urgent market demand. We need €7.5M to build & validate our pilot and expect to generate €125M revenue by 2028 with 105 job